Treatment Optimization Pillar
Development Of Antimicrobial Therapeutics from The Natural Products Of Microbiomes
Project Key Words: Natural Products, Microbial Ecology, Antibiotic Potentiators, Counter-Resistance
Principal Investigator: Joe J. Harrison, PhD
Co-Investigator(s): Kathy McCoy, PhD; Darren Derksen, PhD
Trainees: Rahgavi Poopalarajah, BSc; Shannon Pyke, BSc; Ben Rowley, PhD
Project Theme: Innovation and Commercialization
The proposed program seeks to elucidate microbial chemical interactions that drive the AMR of bacterial communities. This research is predicated on an ecological principle that we term “counter-resistance,” which posits that many Archaea, bacteria and other microbial eukaryotes have evolved the means to produce metabolites that block AMR because of competitive interactions for resources and space.
Why is This Important?
Microbiologists have acquired most of the information known about the genetic and biochemical mechanisms of AMR by studying model organisms in monocultures. However, bacteria are rarely found in any environment alone and we know very little about the scope and impact of polymicrobial interactions on the AMR of even the best-studied model organisms.
We have identified that many bacteria produce low molecular weight molecules (called N-acylamides) that block AMR, including carbapenem-resistance of Pseudomonas aeruginosa and Acenitobacter baumanii. These carbapenem-resistant bacteria top the World Health Organization (WHO) global priority list of antibiotic-resistant pathogens to guide research, discovery, and development of new antibiotics.
Our team has led the development of technology platforms for prospecting chemical microbe-microbe interactions. Our platforms include the Alberta Microbiota Repository (a living library containing hundreds of species of bacteria and fungi native to Canada) and robotics enclosed in air-tight chambers to handle these organisms. We also work with experts in natural product chemistry and processes for identifying bioactive molecules from complex mixtures. We will use synthetic chemistry to execute structure-activity relationship studies of identified biomolecules. Our expertise in biochemistry and molecular genetics will be used to elucidate mode-of-action. Using gnotobiotic animal models, we will investigate the impact of natural antibiotic adjuvants and the microorganisms that produce them on antibiotic therapy outcomes.
Leveraged Sources of Support
- UofC VPR
Knowledge & Technology Exchange and Exploitation
- We will develop molecules that can rescue existing antibiotic drugs from AMR.
- We are developing polymicrobial biofilm susceptibility testing models with a corporate partner.
Highly Qualified Personnel
- 1 PhD Student
- 1 Masters Student
- 1 Post-doctoral Fellow